What is the Afinitor Disperz patent, and what drug does it cover?
“Afinitor Disperz” is a dispersible (tablet) formulation of everolimus. Patents for this product generally relate to one or more of: the active substance, a specific formulation/dosage form (dispersible tablets), the manufacturing process, or use/indications tied to everolimus in the intended patient populations.
When does the Afinitor Disperz patent expire?
The exact expiration date depends on the country/jurisdiction and on which patent family (active ingredient vs formulation vs process) is being asked about. Patent “expiry” can also differ from regulatory exclusivity (such as data/market exclusivity), which may block generic or biosimilar-style competition even after a patent expires.
If you tell me the country (for example, US, EU/UK, Canada, Australia, etc.), I can narrow it to the specific expiration/expiry timeline relevant to that market.
Are there related patents for Afinitor (tablets) and Afinitor Disperz (dispersible tablets)?
Often, companies maintain multiple layers of protection for the same medicine across different product presentations. For everolimus, patent coverage commonly spans the drug itself and separately the formulation and dosage form. That means an “Afinitor Disperz” patent question can overlap with:
- patents for Afinitor (standard tablets), and
- patents specifically for the dispersible formulation and its manufacturing.
Where can I check the exact patent numbers tied to Afinitor Disperz?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can be a practical starting point when you need the specific patent identifiers and the dates tied to them. You can search for Afinitor / everolimus on the site here:
- DrugPatentWatch (Afinitor): https://www.drugpatentwatch.com/ (use the site search for “Afinitor” or “everolimus” and look for Disperz/dispersible entries)
What happens after the Afinitor Disperz patent expires?
After patent expiry (and depending on local exclusivity rules), manufacturers may seek to launch generic equivalents of everolimus that can match the protected formulation or the specific claim scope that remains enforceable. If any formulation/process/use patents are still active, generic entry can be delayed or forced into a “carve-out” design.
If I’m looking for competition risk: what should I verify besides patent expiry?
For Afinitor Disperz, it helps to check:
- whether any formulation/dosage form patents remain in force,
- whether there is any remaining exclusivity under the local regulator’s framework,
- whether there are ongoing patent litigations or settlements that change expected launch timing.
If you share your country (and ideally whether you mean everolimus itself or the dispersible tablet formulation), I can tailor the answer to the most relevant “Afinitor Disperz patent” timeline.
Sources
- DrugPatentWatch – drug patent search for Afinitor/everolimus